Breakdown Products of Fibrin and Fibrinogen: Molecular Mechanisms and Clinical Implications

Total Page:16

File Type:pdf, Size:1020Kb

Breakdown Products of Fibrin and Fibrinogen: Molecular Mechanisms and Clinical Implications J Clin Pathol: first published as 10.1136/jcp.s3-14.1.10 on 1 January 1980. Downloaded from J Clin Pathol, 33, Suppl (Roy Coll Path), 14, 10-17 Breakdown products of fibrin and fibrinogen: molecular mechanisms and clinical implications PJ GAFFNEY From the National Institute for Biological Standards and Control, Holly Hill, Hampstead, London The major terminal enzymatic expression of the Fibrin-plasmin breakdown products fibrinolytic cascade system in vivo is plasmin. This enzyme is piesumed to interact with fibrinogen and FRAGMENTATION MECHANISMS fibrin in vivo and is arguably man's major defence Investigations into molecular fragmentation began against the deposition of fibrin, an important com- in 1945 when Walter Seegers, present-day doyen of ponent in the general hazard of thrombosis. haemostasis research workers, showed that plasmin- Our understanding of the molecular details of digested fibrinogen consisted of two major electro- plasmin interactions with fibrinogen and fibrin has phoretic fragments which were called o-fibrinogen been established over the past 10 years. As a part of and /3-fibrinogen.5 In the first detailed examination the overall strategy to elaborate the primary sequence of the fragments obtained from the interaction of of human fibrinogen the precise locations of the fibrinogen with plasmin Nussenzweig et al.6 distin- peptide bonds ruptured by plasmin at various stages guished five major fractions by ion-exchange copyright. in the degradation process have been reported. Such chromatography. They called these A, B, C, D, and precise data are not available as yet for fibrin- E, and they described fragments D and E as plasmin- plasmin interactions. I shall discuss the major resistant or terminal core fragments with molecular aspects of fibrinogen-plasmin interactions only weights of about 83 000 and 37000 respectively. briefly since these have been recently reviewed by, Fragments D and E were 50% and 20% by weight among others, Mosesson and Finlayson1 and of the original fibrinogen molecule,7 represented Gaffney.2 I shall deal with the current knowledge of immunologically distinct regions of fibrinogen,8 and fibrin-plasmin interactions in more detail since new are synonymous with the o- and fl-fibrinogens of http://jcp.bmj.com/ and exciting data concerning fibrin fragmentation, Seegers.5 Nussenzweig et al.6 also observed inter- which may have significance in vivo, have recently mediate plasmin-labile degradation products of emerged. fibrinogen, subsequently named by other workers In this review I am supposing that the major X, Y fragments.9 breakdown products of fibrinogen and fibrin (FDPs) Examination of the polypeptide compositions of are mediated by plasmin in vivo. Thus the in-vitro the various fragments derived from plasmin- experiments conducted in many laboratories over fibrinogen interactions in conjunction with carbo- on September 27, 2021 by guest. Protected the years have concentrated on plasmin-mediated hydrate staining and thrombin susceptibility of their interactions. It is, however, well to point out that composite peptide chains has allowed a number of the interactions between fibrinogen and a number schemes of fibrinogen fragmentation'0-14 which have of other proteolytic enzymes have also been studied a number of common features. Fig. 1 shows the in vitro (for review see Latallo et al.3). Indeed, major features of a sequence of digestive reactions Moroz and Gilmore4 thought that a variety of and products formed withwhichmost oftheseworkers proteolytic enzymes of cellular origin may play a would now agree. The conservation of both the far more important part in the lysis of established NH2-terminal amino-acids1617 of the Ao-chains thrombin in vivo than does plasmin. Nevertheless, suggests that the initial lysis of the Aa-chain takes there is little doubt that plasmin interacts with place at their carboxy ends. Peptides of about forming fibrin, attempting to prevent its deposition 40 000 molecular weight are released rather rapidly, on the vessel wall. I shall expand this last opinion leaving the NH2-terminal remnant of the Ao-chain when discussing plasmin-fibrin interactions and their disulphide bonded to intact BP and y chains. The significance in vivo. next reaction involves the removal of peptides 10 J Clin Pathol: first published as 10.1136/jcp.s3-14.1.10 on 1 January 1980. Downloaded from Breakdown products offibrin andfibrinogen: molecular mechanisms and clinical implications I1I Fibrinogen Fragment X Fragment Y each subunit of the fibrinogen dimer is random. .1 344000) wt. 300000-260000) (nml wt.150000) N N N Further support has been provided for the asym- metrical mode of fibrinogen fragmentation and the release of D as a monomeric fragment by the finding that the NH2-terminal amino-acids of fibrinogen, X, Y, and E are essentially alanine and tyrosine while those of fragment D are aspartic, methionine, and valine. This locates the D fragment at the carboxy terminal half of the fibrinogen subunit. Subsequently, it has been shown24 that fragment Y FragmenltE contains 2 mol fibrinopeptide A and a set each of (m.1 .t 50000) heavy and light polypeptide chains. These latter C C data seem to have confirmed beyond doubt the Fragment D Fragment D M,t9400) (moL.r.94000) asymmetric scheme of fibrinogen degradation by plasmin shown in Fig. 1. Fig. 1 Diagram ofplasmin-mediated conversion of fibrinogen (Fg) to its core fragments D and E, showing intermediate fragmentts X and Y. Fibrin-plasmin interactions The scheme is constructed so that the polypeptide chain origin of the constituent subunits of each fragment The thrombin-mediated reactions which accompany can be related to those of the preceding fragment and the conversion of fibrinogen to various types of in turn to chains of the originating fibrinogen molecule fibrin must first be outlined. (Aoa, B,, and y). The amino (N)- and carboxy (C)- Fibrin formation is initiated by the cleavage of the terminal ends of the fragments are shown to aid in fibrinopeptides A and B from fibrinogen (ACX2Bfl2y2) visualising the site of structural breakdown more easily. by thrombin.25 The resultant fibrin monomer MWs ( x JO-S) are shown in parentheses after each (U2P2y2) can polymerise to non-stabilised polymers fragment designation. The range of MWs offragment X (a2fl2y2)p, which can subsequently be cross-linked depends on the amount of peptide material removed copyright. from the carboxy ends of the A ce-chains and whether in the presence of calcium and factor XIII (activated the peptides have been hydrolysed from the amino- by thrombin) to form stabilised fibrin.26 The terminal ends of the Bf3 chains. Other details of this glutamyl-lysyl27 28 cross-links form rapidly between asymmetrical scheme offibrinogen fragmentation are the y chains to form y dimers (y-y) while the oa chains in the text. (Taken from Gaffney15; reproduced by kind cross-link more slowly to form x chain polymers permission of the Editor and Publishers of Haemostasis.) (aP) of a molecular weight in excess of 400 000.29 It seems that the y chain cross-links can form in fibrin (MW 6000) from the NH2-terminal ends of the when it is still in the soluble state in plasma2l and http://jcp.bmj.com/ Bf-chainls'2 17-21 followed by the asymmetric splitting the incorporation of of chain cross-links seems to of the three chains at one side of the partly degraded depend on the y chains being already in situ. dimer. These latter cleavages release fragment D, The importance of these cross-links in fibrin and and thus all lysis points must be adjacent to the whether they have the opportunity of forming in vivo NH2-terminal ends of all three chains, allowing that will be discussed later. For the moment it is sufficient fragment D is located near the carboxy end of each to indicate that an understanding is required of the fibrinogen subunit.22 The remaining major fragment interactions of plasmin with at least three major on September 27, 2021 by guest. Protected is called y,9 23 and the subsequent Iysis of its Act, forms of fibrin: (1) non-cross-linked fibrin (NXL- B,B, and y chain remnants converts fragment Y to FN); (2) partly (y-y) cross-linked fibrin (PXL-FN); fragments D and B. Evidently the terminal or 'core' and (3) totally (cx chains and y chains cross-linked) fragments D are made up of three polypeptide chain cross-linked fibrin (TXL-FN). Part of the diagram remnants of the Act, B,B, and y chains of fibrinogen in Fig. 2 shows three fibrin molecules with the while fragment E is a dimer containing disulphide approximate locations of the factor XIII cross-links. bonded subunits, each subunit being made up of The (x chain cross-links have been placed near the three polypeptide chains. carboxy termini for ease of presentation, whereas This scheme of degradation owes much to the we now know that they are located at least 20 000 original scheme of Marder et al.23 in which they MW from the carboxy ends of the cx chains.3' suggested an asymmetrical cleavage of the fibrinogen dimer by plasmin. This type of digestive splitting NON-CROSS-LINKED FIBRIN (NXL-FN) may suggest that the two subunits of this fibrinogen From a chemical viewpoint it is reasonable to dimer differ discretely in primary structure or else regard NXL-FN as being quite similar to fibrinogen, that the sequential release of the D fragments from since its chemical structure lacks only fibrinopeptides J Clin Pathol: first published as 10.1136/jcp.s3-14.1.10 on 1 January 1980. Downloaded from 12 Gaffney CROSS-LINKED FIBRIN (XL-FN) The interaction of plasmin with XL-FN will deal with both PXL-FN and TXL-FN together since the spectrum of fragments obtained from both forms of fibrin is quite similar.38 It would seem that the major property endowed on fibrin by o chain cross-linkage is resistance to lysis by plasmin.39 40 Information about the fragments yielded on lysis of XL-FN by plasmin has slowly unfolded.
Recommended publications
  • Factor XIII and Fibrin Clot Properties in Acute Venous Thromboembolism
    International Journal of Molecular Sciences Review Factor XIII and Fibrin Clot Properties in Acute Venous Thromboembolism Michał Z ˛abczyk 1,2 , Joanna Natorska 1,2 and Anetta Undas 1,2,* 1 John Paul II Hospital, 31-202 Kraków, Poland; [email protected] (M.Z.); [email protected] (J.N.) 2 Institute of Cardiology, Jagiellonian University Medical College, 31-202 Kraków, Poland * Correspondence: [email protected]; Tel.: +48-12-614-30-04; Fax: +48-12-614-21-20 Abstract: Coagulation factor XIII (FXIII) is converted by thrombin into its active form, FXIIIa, which crosslinks fibrin fibers, rendering clots more stable and resistant to degradation. FXIII affects fibrin clot structure and function leading to a more prothrombotic phenotype with denser networks, characterizing patients at risk of venous thromboembolism (VTE). Mechanisms regulating FXIII activation and its impact on fibrin structure in patients with acute VTE encompassing pulmonary embolism (PE) or deep vein thrombosis (DVT) are poorly elucidated. Reduced circulating FXIII levels in acute PE were reported over 20 years ago. Similar observations indicating decreased FXIII plasma activity and antigen levels have been made in acute PE and DVT with their subsequent increase after several weeks since the index event. Plasma fibrin clot proteome analysis confirms that clot-bound FXIII amounts associated with plasma FXIII activity are decreased in acute VTE. Reduced FXIII activity has been associated with impaired clot permeability and hypofibrinolysis in acute PE. The current review presents available studies on the role of FXIII in the modulation of fibrin clot properties during acute PE or DVT and following these events.
    [Show full text]
  • Update on Antithrombin I (Fibrin)
    ©2007 Schattauer GmbH,Stuttgart AnniversaryIssueContribution Update on antithrombinI(fibrin) Michael W. Mosesson 1957–2007) The Blood Research Institute,BloodCenter of Wisconsin, Milwaukee,Wisconsin, USA y( Summary AntithrombinI(fibrin) is an important inhibitor of thrombin exosite 2.Thelatterreaction results in allostericchanges that generation that functions by sequestering thrombin in the form- down-regulate thrombin catalytic activity. AntithrombinIdefi- Anniversar ingfibrin clot,and also by reducing the catalytic activity of fibrin- ciency (afibrinogenemia), defectivethrombin binding to fibrin th boundthrombin.Thrombin binding to fibrin takesplace at two (antithrombin Idefect) found in certain dysfibrinogenemias (e.g. 50 classesofnon-substrate sites: 1) in thefibrin Edomain (two per fibrinogen Naples 1), or areduced plasma γ ’ chain content (re- molecule) throughinteractionwith thrombin exosite 1; 2) at a ducedantithrombin Iactivity),predispose to intravascular singlesite on each γ ’ chain through interaction with thrombin thrombosis. Keywords Fibrinogen,fibrin, thrombin, antithrombin I ThrombHaemost 2007; 98: 105–108 Introduction meric with respecttoits γ chains,and accounts for ~85% of human plasma fibrinogen. Thrombinbinds to its substrate, fibrinogen, through an anion- Low-affinity thrombin binding activity reflects thrombin ex- binding sitecommonlyreferred to as ‘exosite 1’ (1,2). Howell osite1bindinginEdomain of fibrin, as recentlydetailedbyana- recognized nearly acenturyago that the fibrin clot itself exhibits lysesofthrombin-fibrin
    [Show full text]
  • Functional Plasminogen Activator Inhibitor 1 Is Retained on The
    ARTICLE Hemostasis Functional plasminogen activator inhibitor 1 is Ferrata Storti Foundation retained on the activated platelet membrane following platelet activation Gael B. Morrow,° Claire S. Whyte and Nicola J. Mutch Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK °Current address: Radcliffe Department of Medicine, University of Oxford, Oxford, UK Haematologica 2020 Volume 105(12):2824-2833 ABSTRACT latelets harbor the primary reservoir of circulating plasminogen acti- vator inhibitor 1 (PAI-1), but the reportedly low functional activity of Pthis pool of inhibitor has led to debate over its contribution to throm- bus stability. Here we analyze the fate of PAI-1 secreted from activated platelets and examine its role in maintaining thrombus integrity. Activation of platelets results in translocation of PAI-1 to the outer leaflet of the mem- brane, with maximal exposure in response to strong dual agonist stimula- tion. PAI-1 is found to co-localize in the 'cap' of phosphatidylserine-expos- ing platelets with its co-factor, vitronectin, and fibrinogen. Inclusion of tirofiban or Gly-Pro-Arg-Pro significantly attenuated exposure of PAI-1, indicating a crucial role for integrin αIIbb3 and fibrin in delivery of PAI-1 to the activated membrane. Separation of platelets post stimulation into sol- uble and cellular components revealed the presence of PAI-1 antigen and activity in both fractions, with approximately 40% of total platelet-derived PAI-1 remaining associated with the cellular fraction. Using a variety of fib- rinolytic models, we found that platelets produce a strong stabilizing effect against tissue plasminogen activator (tPA)-mediated clot lysis. Platelet lysate, as well as soluble and cellular fractions, stabilize thrombi against premature degradation in a PAI-1-dependent manner.
    [Show full text]
  • The Plasmin–Antiplasmin System: Structural and Functional Aspects
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Bern Open Repository and Information System (BORIS) Cell. Mol. Life Sci. (2011) 68:785–801 DOI 10.1007/s00018-010-0566-5 Cellular and Molecular Life Sciences REVIEW The plasmin–antiplasmin system: structural and functional aspects Johann Schaller • Simon S. Gerber Received: 13 April 2010 / Revised: 3 September 2010 / Accepted: 12 October 2010 / Published online: 7 December 2010 Ó Springer Basel AG 2010 Abstract The plasmin–antiplasmin system plays a key Plasminogen activator inhibitors Á a2-Macroglobulin Á role in blood coagulation and fibrinolysis. Plasmin and Multidomain serine proteases a2-antiplasmin are primarily responsible for a controlled and regulated dissolution of the fibrin polymers into solu- Abbreviations ble fragments. However, besides plasmin(ogen) and A2PI a2-Antiplasmin, a2-Plasmin inhibitor a2-antiplasmin the system contains a series of specific CHO Carbohydrate activators and inhibitors. The main physiological activators EGF-like Epidermal growth factor-like of plasminogen are tissue-type plasminogen activator, FN1 Fibronectin type I which is mainly involved in the dissolution of the fibrin K Kringle polymers by plasmin, and urokinase-type plasminogen LBS Lysine binding site activator, which is primarily responsible for the generation LMW Low molecular weight of plasmin activity in the intercellular space. Both activa- a2M a2-Macroglobulin tors are multidomain serine proteases. Besides the main NTP N-terminal peptide of Pgn physiological inhibitor a2-antiplasmin, the plasmin–anti- PAI-1, -2 Plasminogen activator inhibitor 1, 2 plasmin system is also regulated by the general protease Pgn Plasminogen inhibitor a2-macroglobulin, a member of the protease Plm Plasmin inhibitor I39 family.
    [Show full text]
  • RIASTAP®, Fibrinogen Concentrate (Human) Lyophilized Powder for Solution for Intravenous Injection
    HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------------------CONTRAINDICATIONS ------------------------------------ These highlights do not include all the information needed to use RIASTAP • Known anaphylactic or severe systemic reactions to human plasma-derived products (4). safely and effectively. See full prescribing information for RIASTAP. ---------------------------------WARNINGS AND PRECAUTIONS---------------------------- RIASTAP®, Fibrinogen Concentrate (Human) • Monitor patients for early signs of anaphylaxis or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment (5.1). Lyophilized Powder for Solution for Intravenous Injection • Thrombotic events have been reported in patients receiving RIASTAP. Weigh the benefits of administration versus the risks of thrombosis (5.2). Initial U.S. Approval: 2009 • Because RIASTAP is made from human blood, it may carry a risk of transmitting ------------------------------------RECENT MAJOR CHANGES--------------------------------- infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent Indications and Usage (1) 06/2021 and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent (5.3). Dosage and Administration (2.2) 07/2020 -------------------------------------ADVERSE REACTIONS-------------------------------------- ----------------------------------INDICATIONS AND USAGE----------------------------------- • The most serious adverse reactions observed are thrombotic episodes (pulmonary RIASTAP, Fibrinogen
    [Show full text]
  • Fibrin Induces Release of Von Willebrand Factor from Endothelial Cells
    Fibrin induces release of von Willebrand factor from endothelial cells. J A Ribes, … , C W Francis, D D Wagner J Clin Invest. 1987;79(1):117-123. https://doi.org/10.1172/JCI112771. Research Article Addition of fibrinogen to human umbilical vein endothelial cells in culture resulted in release of von Willebrand factor (vWf) from Weibel-Palade bodies that was temporally related to formation of fibrin in the medium. Whereas no release occurred before gelation, the formation of fibrin was associated with disappearance of Weibel-Palade bodies and development of extracellular patches of immunofluorescence typical of vWf release. Release also occurred within 10 min of exposure to preformed fibrin but did not occur after exposure to washed red cells, clot liquor, or structurally different fibrin prepared with reptilase. Metabolically labeled vWf was immunopurified from the medium after release by fibrin and shown to consist of highly processed protein lacking pro-vWf subunits. The contribution of residual thrombin to release stimulated by fibrin was minimized by preparing fibrin clots with nonstimulatory concentrations of thrombin and by inhibiting residual thrombin with hirudin or heating. We conclude that fibrin formed at sites of vessel injury may function as a physiologic secretagogue for endothelial cells causing rapid release of stored vWf. Find the latest version: https://jci.me/112771/pdf Fibrin Induces Release of von Willebrand Factor from Endothelial Cells Julie A. Ribes, Charles W. Francis, and Denisa D. Wagner Hematology Unit, Department ofMedicine, University ofRochester School ofMedicine and Dentistry, Rochester, New York 14642 Abstract erogeneous and can be separated by sodium dodecyl sulfate (SDS) electrophoresis into a series of disulfide-bonded multimers Addition of fibrinogen to human umbilical vein endothelial cells with molecular masses from 500,000 to as high as 20,000,000 in culture resulted in release of von Willebrand factor (vWf) D (8).
    [Show full text]
  • The Minimum Concentration of Fibrinogen Needed for Platelet Aggregation Using ADP
    RESEARCH ○○○○○○○○ The Minimum Concentration of Fibrinogen Needed for Platelet Aggregation using ADP ROBERT F CORNELL, TIM R RANDOLPH ○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○ OBJECTIVE: Determine the minimum concentration of plasma INDEX TERMS: ADP; aggregation; fibrinogen; platelets. fibrinogen needed to stimulate the aggregation of platelets, col- lected from normal subjects, using ADP. Clin Lab Sci 2001;15(1):30 DESIGN: Platelet rich plasmas (300 x 109 platelets/L) were made Robert F Cornell II was a student in the Department of Clinical and adjusted to final fibrinogen concentrations of 75, 19, 5, and 0 Laboratory Science, Saint Louis University Health Sciences Center, St mg/dL using fibrinogen free serum. Each fibrinogen concentra- Louis MO when this research was done. Downloaded from tion in all twelve subjects was aggregated with ADP. Tim R Randolph MS is an Assistant Professor in the Department of SETTING: Research laboratory in the Department of Clinical Clinical Laboratory Science, School of Allied Health Professions, Saint Laboratory Science at Saint Louis University. Louis University Health Sciences Center, St Louis MO. PARTICIPANTS: Twelve healthy volunteers of both genders, be- Address for correspondence: Tim R Randolph MS, Saint Louis Uni- http://hwmaint.clsjournal.ascls.org/ tween the ages of 18 and 60 years who were not pregnant and versity School of Allied Health Professions, Department of Clinical Labo- weighed at least 110 pounds were included in the study. Subjects ratory Science, Room 3096, 3437 Caroline St, St Louis MO 63104. were excluded from the study if they had ingested aspirin within (314) 577-8518, (314) 577-8503 (fax). [email protected] one week prior to blood collection.
    [Show full text]
  • A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: to Target Or Not to Target?
    International Journal of Molecular Sciences Review A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target? Machteld Sillen and Paul J. Declerck * Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, B-3000 Leuven, Belgium; [email protected] * Correspondence: [email protected] Abstract: Plasminogen activator inhibitor-1 (PAI-1) is the main physiological inhibitor of plasminogen activators (PAs) and is therefore an important inhibitor of the plasminogen/plasmin system. Being the fast-acting inhibitor of tissue-type PA (tPA), PAI-1 primarily attenuates fibrinolysis. Through inhibition of urokinase-type PA (uPA) and interaction with biological ligands such as vitronectin and cell-surface receptors, the function of PAI-1 extends to pericellular proteolysis, tissue remodeling and other processes including cell migration. This review aims at providing a general overview of the properties of PAI-1 and the role it plays in many biological processes and touches upon the possible use of PAI-1 inhibitors as therapeutics. Keywords: plasminogen activator inhibitor-1; PAI-1; fibrinolysis; cardiovascular disease; cancer; inflammation; fibrosis; aging Citation: Sillen, M.; Declerck, P.J. 1. Introduction A Narrative Review on Plasminogen Plasminogen activator inhibitor-1 (PAI-1) belongs to the family of serine protease Activator Inhibitor-1 and Its inhibitors (serpins) and is an important regulator of the plasminogen/plasmin system (Patho)Physiological Role: To Target (Figure1)[ 1]. This system revolves around the conversion of the zymogen plasmino- or Not to Target?. Int. J. Mol. Sci. 2021, gen into the active enzyme plasmin through proteolytic cleavage that is mediated by 22, 2721.
    [Show full text]
  • Protein C Product Monograph 1995 COAMATIC® Protein C Protein C
    Protein C Product Monograph 1995 COAMATIC® Protein C Protein C Protein C, Product Monograph 1995 Frank Axelsson, Product Information Manager Copyright © 1995 Chromogenix AB. Version 1.1 Taljegårdsgatan 3, S-431 53 Mölndal, Sweden. Tel: +46 31 706 20 00, Fax: +46 31 86 46 26, E-mail: [email protected], Internet: www.chromogenix.se COAMATIC® Protein C Protein C Contents Page Preface 2 Introduction 4 Determination of protein C activity with 4 snake venom and S-2366 Biochemistry 6 Protein C biochemistry 6 Clinical Aspects 10 Protein C deficiency 10 Assay Methods 13 Protein C assays 13 Laboratory aspects 16 Products 17 Diagnostic kits from Chromogenix 17 General assay procedure 18 COAMATIC® Protein C 19 References 20 Glossary 23 3 Protein C, version 1.1 Preface The blood coagulation system is carefully controlled in vivo by several anticoagulant mechanisms, which ensure that clot propagation does not lead to occlusion of the vasculature. The protein C pathway is one of these anticoagulant systems. During the last few years it has been found that inherited defects of the protein C system are underlying risk factors in a majority of cases with familial thrombophilia. The factor V gene mutation recently identified in conjunction with APC resistance is such a defect which, in combination with protein C deficiency, increases the thrombosis risk considerably. The Chromogenix Monographs [Protein C and APC-resistance] give a didactic and illustrated picture of the protein C environment by presenting a general view of medical as well as technical matters. They serve as an excellent introduction and survey to everyone who wishes to learn quickly about this field of medicine.
    [Show full text]
  • PROTEIN C DEFICIENCY 1215 Adulthood and a Large Number of Children and Adults with Protein C Mutations [6,13]
    Haemophilia (2008), 14, 1214–1221 DOI: 10.1111/j.1365-2516.2008.01838.x ORIGINAL ARTICLE Protein C deficiency N. A. GOLDENBERG* and M. J. MANCO-JOHNSON* *Hemophilia & Thrombosis Center, Section of Hematology, Oncology, and Bone Marrow Transplantation, Department of Pediatrics, University of Colorado Denver and The ChildrenÕs Hospital, Aurora, CO; and Division of Hematology/ Oncology, Department of Medicine, University of Colorado Denver, Aurora, CO, USA Summary. Severe protein C deficiency (i.e. protein C ment of acute thrombotic events in severe protein C ) activity <1 IU dL 1) is a rare autosomal recessive deficiency typically requires replacement with pro- disorder that usually presents in the neonatal period tein C concentrate while maintaining therapeutic with purpura fulminans (PF) and severe disseminated anticoagulation; protein C replacement is also used intravascular coagulation (DIC), often with concom- for prevention of these complications around sur- itant venous thromboembolism (VTE). Recurrent gery. Long-term management in severe protein C thrombotic episodes (PF, DIC, or VTE) are common. deficiency involves anticoagulation with or without a Homozygotes and compound heterozygotes often protein C replacement regimen. Although many possess a similar phenotype of severe protein C patients with severe protein C deficiency are born deficiency. Mild (i.e. simple heterozygous) protein C with evidence of in utero thrombosis and experience deficiency, by contrast, is often asymptomatic but multiple further events, intensive treatment and may involve recurrent VTE episodes, most often monitoring can enable these individuals to thrive. triggered by clinical risk factors. The coagulopathy in Further research is needed to better delineate optimal protein C deficiency is caused by impaired inactiva- preventive and therapeutic strategies.
    [Show full text]
  • The Procoagulant and Proinflammatory Plasma Contact System
    The procoagulant and proinflammatory plasma contact system Thomas Renné Seminars in Immunopathology ISSN 1863-2297 Semin Immunopathol DOI 10.1007/s00281-011-0288-2 1 23 Your article is protected by copyright and all rights are held exclusively by Springer- Verlag. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your work, please use the accepted author’s version for posting to your own website or your institution’s repository. You may further deposit the accepted author’s version on a funder’s repository at a funder’s request, provided it is not made publicly available until 12 months after publication. 1 23 Author's personal copy Semin Immunopathol DOI 10.1007/s00281-011-0288-2 REVIEW The procoagulant and proinflammatory plasma contact system Thomas Renné Received: 4 May 2011 /Accepted: 20 July 2011 # Springer-Verlag 2011 Abstract The contact system is a plasma protease cascade Keywords Plasma . Factor XII . Thrombosis . Bradykinin . that is initiated by coagulation factor XII activation on Leakage . Edema . Hereditary angioedema cardiovascular cells. The system starts procoagulant and proinflammatory reactions, via the intrinsic pathway of coagulation or the kallikrein–kinin system, respectively. Components of the plasma contact system The biochemistry of the contact system in vitro is well understood, however, its in vivo functions are just begin- Blood coagulation is essential to maintain the integrity of a ning to emerge. Data obtained in genetically engineered closed circulatory system (hemostasis), but may also contrib- mice have revealed an essential function of the contact ute to thromboembolic occlusions of the vessel lumen, which system for thrombus formation.
    [Show full text]
  • Investigating the Role of Von Willebrand Factor in Fibrin Formation and Fibrinolysis
    INVESTIGATING THE ROLE OF VON WILLEBRAND FACTOR IN FIBRIN FORMATION AND FIBRINOLYSIS by Max A Mendez Lopez A thesis submitted in partial fulfilment of the requirements for the degree of Master of Science in Molecular Medicine Supervisor Thomas McKinnon. BSc, PhD. Imperial College of Science, Technology and Medicine September 2014 1 ACKNOWLEDGEMENTS I want to thank Adriana and both of our families for their patience, advice and unconditional support. I am especially grateful with Dr. McKinnon for his guidance and recommendations, these months have been really enjoyable. To Dr. Nowak, Prof. Laffan and the rest of the members of the lab thank you for let me be part of your group. I would also like to acknowledge the Ministry of Science and Technology of Costa Rica, whose financial support has allowed me to undertake this degree. Pura Vida! 2 ABBREVIATIONS Abs Absorbance ADAMTS13 A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) aPTT Activated partial thromboplastin time GP Glycoprotein HK High molecular weight kininogen kDa KiloDaltons kDapp Apparent dissociation constant MW Molecular weight PBS Phosphate buffer saline PK Prekallikrein PT Prothrombin time TF Tissue Factor TAFI Thrombin-Activated Fibrinolysis Inhibitor t-PA Tissue-type plasminogen activator u-PA urokinase-type plasminogen activator VWF Von Willebrand factor 3 TABLE OF CONTENTS Title……………………………………..…………………………………………….…… 1 Acknowledgements……………………………………………………………………..… 2 Abbreviations………………………………………………………………………………3 Table of Contents…………………………………………………………………….…… 4 Abstract…………………………………………………………………………………… 6 List of Figures…………………………………………………………………..………… 7 List of Tables……………………………………………………………………………… 7 1. INTRODUCTION………………………..………………………………………..… 8 1.1 Haemostasis Overview……………………………………………………...…… 8 1.2 The Cell-Based Model of Coagulation…………………………………...……... 8 1.3 The Contact System and The Intrinsic Pathway…………………………..…… 10 1.4 The Extrinsic and Common Pathways……………………………………….… 12 1.5 Fibrinolysis…………………………………………………………………….
    [Show full text]